Business Context and Reporting Period
Company: ORIC Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: February 23, 2026
Reporting Period: Fourth quarter and full year ended December 31, 2025.
The filing serves as a notification that the Company issued a press release announcing its financial results for the specified period. The detailed results are contained in Exhibit 99.1 (Press Release dated February 23, 2026), which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. The following metrics are referenced but not quantified in this document:
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Margins: Not provided in text.
- Debt and Liquidity: Not provided in text.
Investors must refer to the attached Exhibit 99.1 for specific financial figures.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to prior periods. It only confirms the issuance of results for the fourth quarter and full year ended December 31, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing management commentary but does not include the text of that commentary.
Forward-Looking Statements: The filing includes a standard disclaimer stating that information in Item 2.02 and Item 9.01 (including the press release) is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 23, 2026) for actual revenue, net income, and cash flow figures.
- Verify the specific details of the fourth quarter and full-year 2025 performance against prior year guidance.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the Company's liquidity position and cash runway as detailed in the full financial statements.